Neonatal jaundice is a common problem among infants immediately after birth. It is the result of the inability of the neonatal liver to clear bilirubin, a breakdown product of blood cells, from the blood. Neonatal jaundice is usually a self-limiting, mild disorder. The most commonly used treatment is fluorescent light exposure, in which the infant is placed under a lamp for a few hours each day. The blue light breaks down bilirubin into a form the infant liver can process and eliminate.
Less frequently, when neonatal jaundice is more severe, and fluorescent light therapy is unable to break down all circulating bilirubin, exchange transfusion is often used. High levels of bilirubin in the blood can lead to brain damage and other serious problems. In these cases, exchange transfusion is a life-saving procedure designed to counteract the effects of serious jaundice, infection, or toxicity. The procedure involves the staged removal of the infant's blood and replacement with fresh donor blood or plasma.
Guidelines for an exchange transfusion include:
Hemolytic disease of the newborn (Rh disease)
Severe disturbances in body chemistry
Toxic effects of drugs
The infant is laid on his or her back, usually under a radiant warmer. The umbilical vein is catheterized with a fluid-filled catheter. The catheter is connected to an exchange transfusion set, incorporating lines to and from a waste container and a pack of donor blood. These are connected by means of a four-way stopcock, to which is also attached the syringe used to remove and replenish the infant's blood. The exchange transfusion now goes ahead in cycles, each of a few minutes duration. Slowly the infant's blood is withdrawn, and the fresh, pre-warmed blood or plasma is injected. After the exchange transfusion, an umbilical catheter may be left in place in case the procedure needs to be repeated within a few hours.
Neil K. Kaneshiro, MD, MHA, Clinical Assistant Professor of Pediatrics, University of Washington School of Medicine. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.